Skip to main content
Erschienen in: Lung 5/2015

01.10.2015

Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience

verfasst von: David Bennett, Antonella Fossi, Elena Bargagli, Rosa Metella Refini, Maria Pieroni, Luca Luzzi, Claudia Ghiribelli, Piero Paladini, Luca Voltolini, Paola Rottoli

Erschienen in: Lung | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Lung transplantation (LTX) is nowadays accepted as a treatment option for selected patients with end-stage pulmonary disease. Idiopathic pulmonary fibrosis (IPF) is characterized by the radiological and histologic appearance of usual interstitial pneumonia. It is associated with a poor prognosis, and LTX is considered an effective treatment to significantly modify the natural history of this disease. The aim of the present study was to analyse mortality during the waiting list in IPF patients at a single institution.

Methods

A retrospective analysis on IPF patients (n = 90) referred to our Lung Transplant Program in the period 2001–2014 was performed focusing on patients’ characteristics and associated risk factors.

Results

Diagnosis of IPF was associated with high mortality on the waiting list with respect to other diagnosis (p < 0.05). No differences in demographic, clinical, radiological data and time spent on the waiting list were observed between IPF patients who underwent to LTX or lost on the waiting list. Patients who died showed significant higher levels of pCO2 and needed higher flows of O2-therapy on effort (p < 0.05). Pulmonary function tests failed to predict mortality and no other medical conditions were associated with survival.

Conclusions

Patients newly diagnosed with IPF, especially in small to medium lung transplant volume centres and in Countries where a long waiting list is expected, should be immediately referred to transplantation, delay results in increased mortality. Early identification of IPF patients with a rapid progressive phenotype is strongly needed.
Literatur
1.
Zurück zum Zitat Orens JB, Estenne M, Arcasoy S, Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation et al (2006) International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25(7):745–755CrossRefPubMed Orens JB, Estenne M, Arcasoy S, Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation et al (2006) International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25(7):745–755CrossRefPubMed
2.
Zurück zum Zitat Trulock EP, Christie JD, Edwards LB et al (2007) Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report—2007. J Heart Lung Transplant 26(8):782–795CrossRefPubMed Trulock EP, Christie JD, Edwards LB et al (2007) Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report—2007. J Heart Lung Transplant 26(8):782–795CrossRefPubMed
3.
Zurück zum Zitat Meyer KC, Raghu G, Verleden GM, ISHLT/ATS/ERS BOS Task Force Committee et al (2014) An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J 44(6):1479–1503CrossRefPubMed Meyer KC, Raghu G, Verleden GM, ISHLT/ATS/ERS BOS Task Force Committee et al (2014) An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J 44(6):1479–1503CrossRefPubMed
4.
Zurück zum Zitat Raghu G, Collard HR, Egan JJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824CrossRefPubMed Raghu G, Collard HR, Egan JJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824CrossRefPubMed
5.
Zurück zum Zitat Cottin V, Le Pavec J, Prévot G et al (2010) Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 35(1):105–111CrossRefPubMed Cottin V, Le Pavec J, Prévot G et al (2010) Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 35(1):105–111CrossRefPubMed
6.
Zurück zum Zitat Castria D, Refini RM, Bargagli E et al (2012) Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress. Int J Immunopathol Pharmacol. 25(3):681–689PubMed Castria D, Refini RM, Bargagli E et al (2012) Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress. Int J Immunopathol Pharmacol. 25(3):681–689PubMed
8.
Zurück zum Zitat King TE Jr, Bradford WZ, Castro-Bernardini S, ASCEND Study Group et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083–2092CrossRefPubMed King TE Jr, Bradford WZ, Castro-Bernardini S, ASCEND Study Group et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083–2092CrossRefPubMed
9.
Zurück zum Zitat Richeldi L, du Bois RM, Raghu G, INPULSIS Trial Investigators et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071–2082CrossRefPubMed Richeldi L, du Bois RM, Raghu G, INPULSIS Trial Investigators et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071–2082CrossRefPubMed
10.
Zurück zum Zitat Barlo NP, van Moorsel CH, van den Bosch JM, Grutters JC (2010) Predicting prognosis in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 27(2):85–95PubMed Barlo NP, van Moorsel CH, van den Bosch JM, Grutters JC (2010) Predicting prognosis in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 27(2):85–95PubMed
11.
Zurück zum Zitat Egan TM, Murray S, Bustami RT et al (2006) Development of the new lung allocation system in the United States. Am J Transplant 6(5 Pt 2):1212–1227CrossRefPubMed Egan TM, Murray S, Bustami RT et al (2006) Development of the new lung allocation system in the United States. Am J Transplant 6(5 Pt 2):1212–1227CrossRefPubMed
12.
Zurück zum Zitat Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156(10):684–691CrossRefPubMed Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156(10):684–691CrossRefPubMed
13.
Zurück zum Zitat du Bois RM, Albera C, Bradford WZ et al (2014) 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 43(5):1421–1429CrossRefPubMed du Bois RM, Albera C, Bradford WZ et al (2014) 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 43(5):1421–1429CrossRefPubMed
14.
Zurück zum Zitat Raghu G, Collard HR, Anstrom KJ et al (2012) Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 185(10):1044–1048CrossRefPubMed Raghu G, Collard HR, Anstrom KJ et al (2012) Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 185(10):1044–1048CrossRefPubMed
15.
Zurück zum Zitat Mackay LS, Anderson RL, Parry G et al (2007) Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation. Thorax 62(12):1069–1073PubMedCentralCrossRefPubMed Mackay LS, Anderson RL, Parry G et al (2007) Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation. Thorax 62(12):1069–1073PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Report 2014 Organizzazione Toscana Trapianti (OTT) Report 2014 Organizzazione Toscana Trapianti (OTT)
17.
Zurück zum Zitat Andreasson AS, Dark JH, Fisher AJ (2014) Ex vivo lung perfusion in clinical lung transplantation—state of the art. Eur J Cardiothorac Surg 46(5):779–788CrossRefPubMed Andreasson AS, Dark JH, Fisher AJ (2014) Ex vivo lung perfusion in clinical lung transplantation—state of the art. Eur J Cardiothorac Surg 46(5):779–788CrossRefPubMed
18.
Zurück zum Zitat Wigfield C (2014) Donation after cardiac death for lung transplantation: a review of current clinical practice. Curr Opin Organ Transplant 19(5):455–459PubMed Wigfield C (2014) Donation after cardiac death for lung transplantation: a review of current clinical practice. Curr Opin Organ Transplant 19(5):455–459PubMed
19.
Zurück zum Zitat Prasse A, Probst C, Bargagli E et al (2009) Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179(8):717–723CrossRefPubMed Prasse A, Probst C, Bargagli E et al (2009) Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179(8):717–723CrossRefPubMed
20.
Zurück zum Zitat Yokoyama A, Kondo K, Nakajima M et al (2006) Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 11(2):164–168CrossRefPubMed Yokoyama A, Kondo K, Nakajima M et al (2006) Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 11(2):164–168CrossRefPubMed
21.
Zurück zum Zitat Richards TJ, Kaminski N, Baribaud F et al (2012) Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 185(1):67–76PubMedCentralCrossRefPubMed Richards TJ, Kaminski N, Baribaud F et al (2012) Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 185(1):67–76PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Bargagli E, Olivieri C, Cintorino M et al (2011) Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis? Inflammation 34(2):85–91CrossRefPubMed Bargagli E, Olivieri C, Cintorino M et al (2011) Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis? Inflammation 34(2):85–91CrossRefPubMed
23.
Zurück zum Zitat Bargagli E, Madioni C, Bianchi N et al (2014) Serum analysis of coagulation factors in IPF and NSIP. Inflammation 37(1):10–16CrossRefPubMed Bargagli E, Madioni C, Bianchi N et al (2014) Serum analysis of coagulation factors in IPF and NSIP. Inflammation 37(1):10–16CrossRefPubMed
24.
Zurück zum Zitat Korthagen NM, van Moorsel CH, Zanen P et al (2014) Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias. Lung 192(6):975–980CrossRefPubMed Korthagen NM, van Moorsel CH, Zanen P et al (2014) Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias. Lung 192(6):975–980CrossRefPubMed
Metadaten
Titel
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience
verfasst von
David Bennett
Antonella Fossi
Elena Bargagli
Rosa Metella Refini
Maria Pieroni
Luca Luzzi
Claudia Ghiribelli
Piero Paladini
Luca Voltolini
Paola Rottoli
Publikationsdatum
01.10.2015
Verlag
Springer US
Erschienen in
Lung / Ausgabe 5/2015
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-015-9767-x

Weitere Artikel der Ausgabe 5/2015

Lung 5/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.